Immuno-Oncology Research Services
Accelerating Cancer Immunotherapy Development with Advanced Immuno-Oncology Research Services
Developing successful cancer immunotherapies requires more than traditional laboratory testing. Today’s oncology innovators need a deeper understanding of how therapies interact with the immune system, activate anti-tumor responses, and deliver meaningful clinical outcomes.
At ImmunitasBio, we provide comprehensive Immuno-Oncology Research Services that help biotechnology companies, pharmaceutical organizations, and therapeutic developers accelerate Immuno-Oncology Drug Development through scientifically robust, mechanism-driven evaluation strategies.
Our integrated Cancer Immunotherapy Research Services platform generates actionable biological insights that enable sponsors to identify promising therapeutic candidates, reduce development risk, and advance programs with greater confidence.
Whether you are developing Monoclonal Antibodies, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, Peptide Therapeutics, or Next-Generation Cancer Biologics, our team delivers the functional data needed to support critical development decisions.
Our Integrated Immunotherapy Evaluation Platform
As a trusted partner for Preclinical Immuno-Oncology Services, ImmunitasBio combines advanced biology, translational research expertise, and clinically relevant testing models to support the complete immunotherapy development lifecycle.
Our Immunotherapy Evaluation Platform provides:
Functional Immune Profiling Services
Tumor Cell Killing Assays
Immune Cell Activation Assays
Cytokine Profiling Services
Mechanism of Action Studies
Translational Immuno-Oncology Research
Candidate Prioritization Support
The result is a comprehensive biological understanding of your therapeutic candidate before clinical development begins.
Frequently Asked Questions
What are Immuno-Oncology Research Services?
Immuno-Oncology Research Services evaluate how cancer therapies interact with the immune system using functional assays, immune profiling, cytokine analysis, and tumor cell killing studies.
What types of cancer immunotherapies can ImmunitasBio evaluate?
We support monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, peptide therapeutics, immune modulators, and next-generation cancer biologics.
Why are Functional Immune Profiling Services important?
Functional immune profiling helps developers understand how therapies activate immune cells, regulate immune responses, and contribute to anti-tumor efficacy.
What are Tumor Cell Killing Assays?
Tumor Cell Killing Assays measure the ability of immune cells or therapeutic candidates to destroy cancer cells under controlled laboratory conditions.
How do Mechanism of Action Studies support drug development?
Mechanism of Action Studies reveal how therapies produce biological effects, helping improve candidate selection, regulatory submissions, and clinical development strategies.
What is Translational Immuno-Oncology Research?
Translational Immuno-Oncology Research connects laboratory findings with clinical outcomes, helping sponsors generate clinically relevant evidence that supports therapeutic development.
